NEWS
Oragenics Inc. Shows Concussion Drug, ONP-002, Designed for Acute Field-Delivery Stable Across a Wide Temperature Range
Oragenics Inc. (NYSE American: OGEN) has announced that its lead candidate for treating concussion, ONP-002, demonstrates stability across a wide temperature range (-20°C to 104°C). This eliminates the need for cold storage, making it suitable for field use in sports and military operations. Key points:
1. ONP-002 is a new chemical entitydesigned for intranasal delivery to treat concussions.
2. The drug maintains over 99% purity after 3 months at various temperatures.
3. Formulated as a spray-dried powder for improved stability.
4. No FDA-approved pharmaceutical treatment currently exists for concussions.
5. An estimated 69 million concussions are reported annually worldwide.
Oragenics aims to address the unmet medical need for concussion treatment, potentially impacting related neurological disorders like Alzheimer's, Parkinson's, and CTE.
1. ONP-002 is a new chemical entitydesigned for intranasal delivery to treat concussions.
2. The drug maintains over 99% purity after 3 months at various temperatures.
3. Formulated as a spray-dried powder for improved stability.
4. No FDA-approved pharmaceutical treatment currently exists for concussions.
5. An estimated 69 million concussions are reported annually worldwide.
Oragenics aims to address the unmet medical need for concussion treatment, potentially impacting related neurological disorders like Alzheimer's, Parkinson's, and CTE.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment
Spread kindness and love. Life is short. Don’t let greed eat you.
1191Followers
74Following
8432Visitors
Follow